CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD. Chongqing Pharscin Pharmaceutical Co., Ltd. Share Price
Equities
002907
CNE100003308
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.31 CNY | -0.30% |
|
+3.98% | -13.85% |
| 04-03 | Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets | MT |
| 01-24 | Pharscin Pharmaceutical Amends Colon Cleanser Drug's Validity Period | MT |
| Sales 2021 | 846M 117M 9.35B | Sales 2022 | 785M 108M 8.68B | Capitalization | 8.5B 1.17B 93.99B |
|---|---|---|---|---|---|
| Net income 2021 | 91M 12.56M 1.01B | Net income 2022 | 98M 13.52M 1.08B | EV / Sales 2021 | 8.26 x |
| Net cash position 2021 | 259M 35.81M 2.87B | Net cash position 2022 | 503M 69.47M 5.56B | EV / Sales 2022 | 10.2 x |
| P/E ratio 2021 |
78.9
x | P/E ratio 2022 |
83.4
x | Employees | 1,416 |
| Yield 2021 |
0.28% | Yield 2022 |
0.34% | Free-Float | 9.66% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.30% | ||
| 1 week | +3.98% | ||
| Current month | -5.06% | ||
| 1 month | -4.52% | ||
| 3 months | -8.71% | ||
| 6 months | -19.24% | ||
| Current year | -13.85% |
1 week
12.55
14.03
1 month
12.2114.51
Current year
9.8217.43
1 year
9.8220.50
3 years
9.8234.85
5 years
9.8234.85
10 years
5.9847.92
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Ying Liu
CEO | Chief Executive Officer | 61 | 18/08/15 |
Kai Yu Xu
CHM | Chairman | 58 | 30/09/00 |
Xiao Yan Peng
DFI | Director of Finance/CFO | 50 | 28/02/02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jia Ming Li
BRD | Director/Board Member | 58 | 17/05/22 |
Shou Ying Du
BRD | Director/Board Member | 64 | 30/04/20 |
Hong Tao You
CHM | Chairman | 61 | 18/08/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 13.31 | -0.30% | 2,814,736 |
| 25/04/24 | 13.35 | +0.68% | 3,522,891 |
| 24/04/24 | 13.26 | +1.14% | 1,578,711 |
| 23/04/24 | 13.11 | +2.10% | 2,247,120 |
| 22/04/24 | 12.84 | +0.31% | 1,651,301 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Chongqing Pharscin Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs and chemical drugs. The Company operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The Company's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Companyâs products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The Company mainly distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
28/04/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -13.85% | 767M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 002907 Stock
